Key result
CCR9 deficiency attenuated pressure overload-induced cardiac hypertrophy, whereas CCR9 overexpression enhanced it via the AKT-mTOR-GSK3β signaling cascade.
Why the study?
Does CCR9 modulation affect pressure overload-induced cardiac hypertrophy in preclinical models?
Does CCR9 modulation affect pressure overload-induced cardiac hypertrophy in preclinical models?
CCR9 promotes maladaptive cardiac hypertrophy via the AKT-mTOR-GSK3β signaling pathway, highlighting it as a potential therapeutic target for heart failure.
Should not inform clinical practice; leaves open CCR9 as a therapeutic target in human heart failure.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2016) studied Cardiac hypertrophy. CCR9 deficiency or overexpression vs. Wild-type or control was evaluated on Pressure overload-induced cardiac hypertrophy. CCR9 deficiency attenuated pressure overload-induced cardiac hypertrophy, whereas CCR9 overexpression enhanced it via the AKT-mTOR-GSK3β signaling cascade.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: